Ultragenyx Pharmaceutical Inc. reported Q4 and FY 2025 financial results and announced a strategic restructuring plan involving a 10% workforce reduction and $50 million in charges. The company also provided 2026 revenue guidance and updated its path to profitability for 2027.
Key takeaways
Total revenue for the year ended December 31, 2025 was $673 million, a 20% increase compared to the prior year.
The Company initiated a restructuring plan on February 12, 2026, reducing its workforce by approximately 130 employees (10%).
Total restructuring charges are estimated at approximately $50 million, primarily related to severance and termination of manufacturing agreements.
2026 total revenue guidance is projected to be between $730 million and $760 million.
Net loss for the year ended December 31, 2025 was $575 million, or $5.83 per share.
Cash, cash equivalents, and marketable securities were $737 million as of December 31, 2025.